BioSpace News Archive

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it will celebrate the opening of its Axogen Processing Center with leaders of the Ohio community on June 12, 2024.

Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases.

Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.

Tarsier Pharma, Ltd, a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing first-in-class new therapies for the treatment of blinding ocular diseases proudly announces the appointment of Emilee Fulcher as Vice President of Clinical Affairs.

ILiAD Biotechnologies, LLC (ILiAD) reported today that BPZE1, the most advanced next generation pertussis vaccine, demonstrated positive topline interim results in the SUPER (Stand Up to Pertussis) school-age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.

palleos healthcare GmbH, a German-based oncology-focused contract research organization, and OCT Global SA operating under OCT Clinical brand name, a full-service CRO in Eastern Europe, are delighted to announce a merger of the two companies, marking a significant milestone in their shared journey towards creating a powerhouse in the field of clinical research.

Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.

The Bill & Melinda Gates Medical Research Institute announced the appointment of Patrice Matchaba, MD, as Chief Executive Officer, starting June 10, 2024.